A clinical investigation was carried out to evaluate arbekacin, an aminoglycoside, in the treatment of MRS A infections (pneumonia, septicemia, etc.) of pediatric patients. the obtained results are summarized as follows. 1. Clinical results: Excluding those patients who met the present exclusion criteria and withdrawal cases from a total of 18 patients, 10 patients (3, 6, and 1 cases of septicemia, pneumonia, and urinary tract infection, respectively) were subjected to clinical evaluation. These were composed of 1, 1, 6, and 2 cases of neonate, infants, pre- and school age children, respectively. Excellent, good and fair results were obtained in 5, 2, and 3 patients, respectively; thus, the efficacy rate was 70.0%. the efficacy rate by disease was 100%, 50.0% and 100% in septicemia, pneumonia, and urinary tract infection, respectively. the bacteriological eradications were obtained in 70.0% of the total patients; by disease, these rates were 100% and 50.0% in septicemia/urinary tract infection and in pneumonia, respectively. the MIC50 as well as the MIC80 against MRS A strains isolated from 9 patients were 0.39 μg/ml and 1.56μg/ml, respectively. No adverse reactions were observed in the 15 patients, while in laboratory test values, one case each out of 12 patients examined showed 7-GTP elevation, proteinuria, and hematuria. 2. Pharmacokinetics: the pharmacokinetics of the agent was investigated in a total of 9 patients, which included 1 neonate and 4 cases each of pre- and school age children. the Cmax, 4.85~8.83 μg/ml, was observed immediately after the termination of the instillation. the T 1/2's were 4.96 hours, 1.24~2.54 hours, and 1.78~1.88 hours in the neonate, the pre- and the school age children, respectively; in the neonate the half-life was longer. When 1.92~2.7 mg/kg were administered to 3 each of the pre- and school age children, urinary excretion rates in the first 6~8 hours were 40.1~56.5% of the dosages administered. in all cases, the urinary concentrations were highest in the first 2 hours, after the dministration, and then gradually decreased. These results suggest that arbekacin is a useful antibiotic for treating MRSA infections in the pediatric field.
ASJC Scopus subject areas